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Introduction
A rapid outbreak of coronavirus disease 2019 (COVID-19) that arises from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, originates in Wuhan city, Hubei province in China and has become a global threat. 1, 2 COVID-19 can result in severe illnesses such as acute respiratory distress syndrome (ARDS), multiorgan dysfunction syndrome (MODS), and resultant death. [1] [2] [3] The World Health Organization (WHO) declared the SARS-CoV-2 a public health emergency of international concern on 30 th Jan. As of February 16th, 2020, 58,873 laboratory-confirmed cases and 1,699 deaths have been documented globally. 4 Considerable differences in disease severity and patient mortality in Hubei province with other parts of China have been documented. 5 Most primarily infected patients have been identified and treated in Hubei province, predominantly have close exposure to Wuhan. This is because Wuhan, the epicenter of COVID-19, is the administrative center of Hubei province and the majority of the population displaced from Wuhan have temporarily relocated to other areas of Hubei. But contrary to the initial wave of cases, an increasing number of patients have been diagnosed outside Wuhan and/or Hubei province, many of whom did not have close contact with people from Wuhan. These patients were more likely to have been infected by secondary or tertiary transmission of SARS-CoV-2. Other investigators have assumed that the high percentage of patients with Wuhan-related exposure (indicating potentially higher virulence) drove the severe situation in Hubei. 6 Exploring the difference between patients in and outside the highly endemic area, as well as by primary and progeny virus, may help clinicians better appreciate the evolution of SARS-CoV-2, and lead to more efficient allocation of healthcare resources. In addition, the exploration of the driving forces underlying these observations such as virus virulence and temporary shortage of health resources may help inform clinical practice and disease prevention. In this nationwide study, we sought to compare the clinical characteristics and outcomes of patients with COVID-19 between these populations, and explore the factors contributing to these differences.
Methods

Data sources
On behalf of the National Clinical Research Center for Respiratory Disease, and collaborating with the National Health Commission of the People's Republic of China, we have established a retrospective cohort to study the COVID-19 cases throughout China. We obtained medical records and compiled the data from laboratory-confirmed hospitalized cases with COVID-19 reported to the China National Health Commission between November 21 st , 2019 and January 31 st , 2020. The National Health Commission requested that all hospitals submit clinical records to the database. Hospitals whose clinical records had not been submitted by this deadline were requested again by the National Health Commission. Confirmed cases of COVID-19 were defined as patients who tested positive by high-throughput sequencing or real-time reverse-transcription polymerase-chain-reaction (RT-PCR) assay for nasal and pharyngeal swab specimens. Only laboratory-confirmed cases were included in our analysis.
Data extraction and processing
A team of experienced respiratory clinicians reviewed and abstracted the data. Data were entered into a computerized database and cross-checked. In the surveillance cohort, we included all patients in the daily report, with only the location and patient's clinical status (severity, live and discharge status). In the core cohort, baseline, examination and treatment information was available and collected. The recent exposure history, clinical symptoms and signs, and laboratory findings upon admission were extracted from electronic medical records. Radiologic assessments, including chest X-ray or computed tomography (CT), were performed based on the documentation/description in medical charts or combined with, if imaging films were available, a review by our medical staff. Major disagreement between two reviewers was resolved by consultation with the third reviewer. We defined the severity of COVID-19 (severe vs. non-severe) based on the American Thoracic Society guidelines for community-acquired pneumonia given its extensive acceptance. 7 Patients with Wuhan-related exposure were defined as patients who lived in or recently traveled to Wuhan, or had recent close contact with people from Wuhan, confirmed by China centers for disease control and prevention (CDC) according to the self-report by patients and survey by the local CDC staff. We compared the differences in clinical characteristics and treatments. In terms of prognosis, the primary endpoint was critical illness including admission to the intensive care unit (ICU), or invasive ventilation, or death. We adopted this endpoint because admission to ICU, invasive ventilation, and death are serious outcomes of COVID-19 that have been adopted in a previous study to assess the severity of other serious infectious diseases, such as the avian influenza H7N9 virus. 8 Secondary endpoints consisted of the mortality rate, and the time from symptom onset to the critical illness and each of its components. We specifically examined the duration from symptom onset to admission.
Due to the great confounding impact of age and comorbidity on the prognosis of COVID-19, we sought to evaluate the prognostic effect of each candidate variable based on adjustment for age and comorbidity [including chronic obstructive pulmonary disease (COPD), diabetes mellitus, hypertension, coronary heart disease, cerebrovascular disease, viral hepatitis type B, malignant tumor, chronic kidney disease and immunodeficiency]. Therefore, we pre-planned several Cox regression analyses to evaluate the prognostic impact of 1) Hubei location alone; 2) Wuhan-related exposure alone; and 3) Wuhan-related exposure in patients outside Hubei. In addition, we planned to test a hypothesis that the time from symptom onset to hospitalization might underly the difference in prognosis between the location and contact history. Thus, we included Hubei location, Wuhan-related exposure, time from symptom onset to hospitalization, age and comorbidity in a Cox model.
Statistical analysis
Continuous variables were expressed as the means and standard deviations or medians and interquartile ranges (IQR) as appropriate. Categorical variables were summarized as the counts and percentages in each category. Wilcoxon rank-sum tests were applied to continuous variables, chi-square tests and Fisher's exact tests were used for categorical variables as appropriate. The risk of reaching to the critical illness and the potential risk factors were analyzed using proportional hazard (PH) Cox regression models when PH assumption was not violated. We tested the PH assumption by modeling the log-log of survival curve using each variable included as strata, if the curve did not cross at all time points, the PH assumption was considered not violated. The hazards ratio (HR) along with the 95% confidence interval (95%CI) were reported. To visualize the probability of reaching critical illness of different categories, we presented the hazard function curves estimated by Cox regression model which have adjusted for all included confounders. The significance of the difference between the curves were obtained from the Cox regression model. Significance level was set at P value <0.05. All analyses were conducted with SPSS software version 23.0 (Chicago, IL, USA).
Role of the funding source
The funder had no role in the study design, data collection, analysis and interpretation, or writing of the report. The corresponding authors had full access to all data and had the final responsibility for the decision to submit for publication.
Results
Nationwide Epidemiology Surveillance of COVID-19
Up to January 31st, 2020, a total of 11,791 patients with laboratory-confirmed COVID-19 were identified in China. The flowchart of cohort establishment was shown in Figure S1 . Of these, 7,153 (60.7%) patients were identified in Hubei province. The severe cases accounted for 15.9% of the whole cohort, and 19.2% and 11.0% within and outside Hubei province, respectively. The overall mortality was 2.20% throughout China (3.48% in Hubei province, 0.22% outside Hubei province) (Figure 1) . The latest data has shown a similar trend as of February 15, 2020 (Figure S1&2).
Patient characteristics in the core cohort
In the core cohort, we have collected 1,590 cases from 575 hospitals in 31 provincial administrative regions (full list in online supplement p4-9) upon data cut-off on Jan 31st. Our dataset covered 13.4% (1,590/11,791) of all cases being reported and covered 91.2% of regions (31/34) that had confirmed cases (Figure 2) . Overall, the mean age was 48.9 years; 904 patients (57.3%) were males and 399 (25.1%) had coexisting conditions, including hypertension (269 [16.9%]), diabetes (130 [8.2%]), and cardiovascular disease (59 [3.7%]). Fever (88.0%), dry cough (70.2%), fatigue (42.8%), productive cough (36.0%), and shortness of breath (20.8%) were the most common symptoms. Most patients (71.1%) had abnormal chest CT manifestations. The overall rate of severe cases and mortality was 16.0% and 3.2%, respectively. Details were summarized in Table 1 .
Patients treated inside Hubei and outside Hubei
As shown in Table 1 , 40.7% of the patients from the core dataset were hospitalized in Hubei province (647/1590). Most patients (597/647, 92.3%) in Hubei province had Wuhanrelated exposure. Patients in Hubei province were older (mean: 55.1 vs. 44.6 years) and had more cases with comorbidity (32.9% vs. 19.7%). Patients in Hubei province had a higher symptomatic burden including fatigue (46.4% vs. 40.3%), productive cough (40.2% vs. 33.1%), shortness of breath (36.3% vs. 10.2%), myalgia or arthralgia (20.3% vs. 15.5%), nausea or vomiting (8.1% vs. 4.2%), hemoptysis (2.3% vs. 0.5%), and unconsciousness (2.7% vs. 0.5%), but not pharyngalgia (11.3% vs. 17.0%) compared to non-Hubei patients. Moreover, patients in Hubei province were more likely to have abnormal chest radiograph (18.1% vs. 13.4%) and CT (74.7% vs. 68.6%) manifestations. Patients in Hubei province also had a longer duration from symptom onset to hospitalization (5.7 vs. 4.5 days) compared with patients outside of Hubei province.
Patient with vs. without Wuhan-related exposure
The majority of patients (1,334/1,590, 83.9%) in this dataset had Wuhan exposure history (18.1% lived in Wuhan, 36.7% recently traveled to Wuhan, and 45.1% had recent contact with people from Wuhan). Compared with those that had no exposure to Wuhan, Wuhanexposed patients were significantly older (mean: 49.7 vs. 44.9 years) and had more cases with comorbidity (26.3% vs. 18.8%, P=0.012), including hypertension (18.1% vs. 10.5%), diabetes (8.8% vs. 4.7%), and malignancy (1.3% vs. 0%); fever (88.0% vs. 87.7%), fatigue (43.2% vs. 40.7%), and shortness of breath (21.8% vs. 15.6%). Furthermore, abnormal manifestation in chest radiograph (16.2% vs. 10.5%) and CT (71.9% vs. 66.8%) were more commonly seen in patients with Wuhan-related exposure than their counterparts. Table 1 summarized detailed information.
Patient with vs. without Wuhan-related exposure outside Hubei
Of 943 patients outside of Hubei province, 737 (78.2%) reported Wuhan-related exposure. There were no differences in patient's clinical characteristics, signs, comorbidities, the rate of abnormal chest images, and most symptoms between patients with and without Wuhanrelated exposure. However, Wuhan-related patients reported less productive cough (30.5% vs. 43.8%) and shortness of breath (8.7% vs. 15.5%) than their counterparts. See details in Table 2 . The duration from symptom onset to hospitalization was similar between patients with and without Wuhan-related exposure (mean: 4.4 vs. 4.7 years) treated outside of Hubei province.
Prognostic analyses
As shown in Figure 3 , both patients treated in Hubei province (23.0% vs. 11.1%, P<0.001) and those with Wuhan-related exposure (16.9% vs. 11.3%, P=0.026) had more severe or fatal cases compared to their counterparts. Similarly, Hubei patients (7.3% vs. 0.3%, P<0.001) and patients with Wuhan-related exposure (3.6% vs. 0.8%, P=0.017) had a higher mortality rate. After adjusting for age and comorbidity, the Cox regression model without PH assumption violation revealed that patients in Hubei province (HR 1.59, 95%CI 1.05-2.41; P=0.027, figure 4A ) and those with Wuhan exposure history (HR 1.34, 95%CI 0.70-2.57; P=0.385, figure 4B) were more likely to reach critical illness. Details were summarized in Table S1-3.
We further subdivided patients with Wuhan-related exposure according to the location of hospitals. Patients with Wuhan exposure history who underwent treatment outside of Hubei province had a better prognosis compared with those treated in Hubei (HR 0.57, 95%CI 0.36-0.91, P=0.018, Figure 4C ) , and yielded similar outcomes compared with patients with no Wuhan exposure history (HR 0.84, 95%CI 0.40-1.80, P=0.653, Figure 4C&D ). Most importantly, after being included in the Cox regression model, the duration from symptom onset to hospitalization, but not Hubei or Wuhan-related exposure, remained an independent factor of the prognosis among the general population (HR 1.05, 1.01-1.08, P=0.005) ( Table 3 ).
Discussion
Although the pandemic has lessened in China and the results reported here focused on the early stage of the outbreak, an increasing number of patients have been diagnosed outside China and some other areas have become new epicenters, such as Lombardia, Italy and Madrid, Spain. Summarizing the experience from China and providing in-depth understanding of the situation in the previous epicenter can help to improve the strategy in the current epicenters. For the situation outside of the epicenter Hubei, two studies presented characteristics and outcomes among patients outside Hubei in Shenzhen and Zhejiang, however, the sample size is small therefore, comparison to Hubei patients cannot be performed. 9, 10 To our knowledge, this is the first nationwide study in China investigating the differences in the clinical characteristics and the prognosis of patients with COVID-19 between both those in and outside of Hubei province, and those with and without Wuhanrelated exposure. We believe that our core cohort could partially represent the overall situation as of Jan 31 st , taking into account the patient number (13.4% of all cases) and the broad coverage (covering almost all major provinces/cities/autonomous regions). Moreover, this dataset showed consistent epidemiological characteristics with the surveillance dataset, indicating that it represented the real-world conditions. Compared with those with contact history with people from Wuhan or living in Hubei province, patients without Wuhan-related exposure or living outside of Hubei were younger, had fewer comorbidities, less abnormal chest radiographic manifestations, and slightly lower symptom burden. These findings suggested a potentially augmented infectivity in the general population beyond fragile individuals (i.e., the elderly). This is in agreement with the median reproduction number (R0), which has increased from 2.0 in early studies to 3.8 in more recent studies. 11, 12 In addition, viral genome sequencing of cases from Hubei province and other regions/countries has also lent support to the continuous revolution in the viral functional regions that facilitates its transmission among the human population (self-adaptation). 13 However, we should be cautious about the bias resulting from the undiagnosed cases in the early phase of transmission when most people were not aware of this disease.
It has been believed that the onward transmission of a virus might result in attenuated disease. 14, 15 Our results showed fewer severe events and a lower mortality rate among patients outside of Hubei province and patients that had no history of Wuhan-related exposure. However, these results might have been biased by the temporary shortage of health resources, such as the limited hospital performance and detection capacity, that resulted from the sudden outbreak of COVID-19 in Hubei. After the surge of cases in January 2020, hospitals in Hubei province were heavily overloaded and managed an overwhelming increase in the number of patients. These shortages could have led to a delay in the diagnosis and treatment of patients, which further contributed to the worsening of overall status upon admission and an increased risk of death.
In this study, we have included the duration from symptom onset to admission to evaluate the impact of the healthcare capacity on the difference between Hubei and other regions in China. Significantly longer waiting time was observed among patients in Hubei province, whereas patients with or without Wuhan-related exposure shared similar waiting time outside of Hubei province. Importantly, we have found that the prolonged waiting time, rather than the geographic location or the Wuhan-related exposure history, predicted the clinical prognosis of COVID-19. We speculated that some patients from Wuhan traveled to other cities outside of Hubei province seeking more timely treatment. These patients reported a similar waiting time and medical care records, which translated into a similar prognosis with the local residents. Consistently, the incidence of severe cases and mortality continuously decreased (figure S1) since clinicians, nurses, and medical instruments have been dispatched to Hubei province. On the other hand, timely screening of candidates with suspected symptoms or contact with confirmed cases might help promptly initiate medical care, thus preventing further spreading of the disease.
There are some limitations of this study. First, although we made every effort to collect data from all patients, some hospitals did not answer our request. Thus, although the dataset had a broad coverage of all patients and regions, the non-responsive bias cannot be fully excluded. Second, the date of symptom onset is self-report based, bias from patient recall might exist. Third, we cannot evaluate the exact healthcare capacity of each hospital but used a duration from symptom onset to admission as an indirect measure. Fourth, only a small proportion of patients had Wuhan exposure history, which may give a non-balanced result with some possible bias. Fifth, some other factors that may have impact on the prognosis, e.g. secondary infection, cannot be evaluated in this study. In addition, a significant proportion of people infected by the SARS-CoV-2 are asymptomatic and were not included in this study of hospitalized patients, the situation in the general infected population requires further studies.
Our findings indicate that the temporary shortage in health capacity in the outbreak epicenter, rather than the transmission history, has resulted in the large number of severe cases or deaths in Hubei province. These results have expanded our understanding of patients infected by secondary or tertiary transmission which will account for the majority of patients that are infected worldwide, and provided timely and important implications for basic research and establishing public health policy. Adequate management of health care resources as well as the public's response is important to mitigate the impact of the outbreak. This study highlights the necessity of urgent and vigorous support of healthcare resources and increased public awareness during the early stages of an outbreak of COVID-19 or similar diseases. 
Figure legends
Clinical characteristics and outcomes of hospitalized patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A Nationwide Analysis of China
Online Supplement Figure S1 . The flowchart of cohort establishment
As of February 15 th , 2020, a total of 68,500 laboratory-confirmed cases have been identified in China. The largest percentage (82.12%) of cases were diagnosed in Hubei province (56,249 patients). The percentage of cases with severe pneumonia in Hubei province (21.20%) was higher than that outside of Hubei province (10.45%). The mortality was also higher in Hubei province (2.84% vs. 0.56%). (Figure S3 ). Figure S2 shows the change of mortality rate in Hubei province, regions outside of Hubei province and the overall population who had laboratory-confirmed COVID-19. 1.336 0.695 2.57 0.385 HR: hazards ratio; LL: lower limit of the 95% confidence interval; UL: upper limit of the 95% confidence interval. Comorbidity included chronic obstructive pulmonary disease (COPD), diabetes mellitus, hypertension, coronary heart disease, cerebrovascular disease, viral hepatitis type B, malignant tumor, chronic kidney disease and immunodeficiency 0.841 0.395 1.79 0.653 HR: hazards ratio; LL: lower limit of the 95% confidence interval; UL: upper limit of the 95% confidence interval. Comorbidity included chronic obstructive pulmonary disease (COPD), diabetes mellitus, hypertension, coronary heart disease, cerebrovascular disease, viral hepatitis type B, malignant tumor, chronic kidney disease and immunodeficiency
